Brief: Antengene Says It Has Entered Into A Global Clinical Collaboration With MSD To Evaluate ATG-037 In Combination With Keytruda

Antengene

27/12/2022 24:35

Dec 26 (Reuters) - Antengene Corporation Ltd  6996.HK :
    * ANTENGENE ENTERS INTO A GLOBAL CLINICAL COLLABORATION WITH
MSD
TO EVALUATE ATG-037 (CD73 INHIBITOR) IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB)
    * STUDY OF ATG-037 MONOTHERAPY STARTED ENROLLING PATIENTS IN
Q2
2022 AND WILL INCLUDE COMBINATION WITH KEYTRUDA® IN 2023
    * ANTENGENE - PRIMARY OBJECTIVE OF STAMINA-001 STUDY IS TO
EVALUATE SAFETY AND TOLERABILITY OF ATG-037 AS MONOTHERAPY AND
IN COMBINATION WITH KEYTRUDA
    * SECONDARY OBJECTIVES OF STUDY INCLUDE CHARACTERIZATION OF
PHARMACOLOGY AND EVALUATION OF PRELIMINARY EFFICACY OF ATG-037
    * ANTENGENE  - UNDER TERMS OF AGREEMENT, STUDY WILL BE
CONDUCTED
BY ANTENGENE, AND MSD WILL PROVIDE KEYTRUDA FOR COMBINATION
PORTIONS OF TRIAL.

Source text for Eikon:  ID:nPn91h86ma 
Further company coverage:  6996.HK 
 ((Reuters.Briefs@thomsonreuters.com;))